ULIXERTINIB |
ULIXERTINIB : Inhibitor of MAPK1, MAPK3
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| MAPK1 |
| |
| MAPK3 |
Inhibitor
up to 1 uM
Selectivity
In Vitro Selectivity Assessment
Selectivity Assessment Description:
BVD-523 demonstrated ERK1/2 kinase selectivity based on biochemical counter-screens against 75 kinas ...
Potency Cellular
In Vitro
MAPK1
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/acs.jmedchem.5b00466
MAPK3
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/acs.jmedchem.5b00466
In Vivo Validations
Mouse
Dose: 1 mg/Kg
Route of delivery:
Intravenous
Plasma half life:
1.16 h
Systemic clearance:
7.90 mL/min/kg
Area Under the Curve::
2109 ng*h/mL
Volume of Distribution at Steady-State:
0.79 L/kg
DOI Reference: 10.1016/j.jpba.2016.03.036
Dose: 10 mg/Kg
Route of delivery:
Oral
Plasma half life:
2.74 h
Cmax:
8104 ng/mL
Tmax:
0.5 h
Area Under the Curve::
23425 ng*h/mL
Bioavailability:
100%
DOI Reference: 10.1016/j.jpba.2016.03.036
Chemical Information
| Molecular Formula | C21H22Cl2N4O2 |
| SMILEs | CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1 |
| InChI | InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1 |
| Molecular weight | 432.11 Da |
| AlogP | 4.667200000000003 |
| HBond acceptors | 6 |
| HBond donors | 4 |
| Atoms | 51 |
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.